Perseverance Research Center

The trials here

What the 9 trials at this site are about, from their registry records.

Conditions

• Alzheimer disease4 trials
• Multiple sclerosis3 trials
• Atopic dermatitis (eczema)1 trial
• Mild cognitive impairment1 trial
• Obesity1 trial
• Type 2 diabetes1 trial

Phase

• Phase 35 trials
• Phase 24 trials

Status

• Active, not recruiting3 trials
• Completed3 trials
• Recruiting2 trials
• Terminated1 trial

Lead sponsor

• Eli Lilly and Company2 trials
• Zenas BioPharma (USA), LLC2 trials
• Novartis Pharmaceuticals1 trial
• Otsuka Pharmaceutical Development & Commercialization, Inc.1 trial
• RAPT Therapeutics, Inc., a member of the GSK plc group of companies1 trial
• and 2 more

Running trials

• Recruiting

  A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis

  NCT07067463· Phase 3· Zenas BioPharma (USA), LLC· Source

• Recruiting

  Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.

  NCT06846281· Phase 3· Novartis Pharmaceuticals· Source

  Contact: Adriana Romero

• Active, not recruiting

  A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone)

  NCT06564311· Phase 2· Zenas BioPharma (USA), LLC· Source

• Active, not recruiting

  Allopregnanolone Regenerative Therapeutic for Mild Alzheimer's Disease

  NCT04838301· Phase 2· University of Arizona· Source

• Active, not recruiting

  A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)

  NCT04437511· Phase 3· Eli Lilly and Company· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Multiple sclerosis2 recruiting

Closed trials

• Terminated

  An Efficacy and Safety Study of RPT193 in Adults With Atopic Dermatitis

  NCT05399368· Phase 2· RAPT Therapeutics, Inc., a member of the GSK plc group of companies· Source

• Completed

  A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight

  NCT04184622· Phase 3· Eli Lilly and Company· Source

• Completed

  Assessment of the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

  NCT03393520· Phase 3· Otsuka Pharmaceutical Development & Commercialization, Inc.· Source

• Completed

  Memory Improvement Through Nicotine Dosing (MIND) Study

  NCT02720445· Phase 2· University of Southern California· Source